X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://pharmaphorum.com/news/first-rare-disease-therapies-chosen-fda-start-programme
https://www.fiercebiotech.com/research/fda-selects-denali-neurogene-larimar-and-grace-sciences-rare-disease-therapy-pilot
https://www.globenewswire.com/news-release/2024/05/30/2891132/0/en/Larimar-Therapeutics-Selected-by-FDA-to-Participate-in-START-Pilot-Program-for-Nomlabofusp-in-Friedreich-s-Ataxia.html
https://www.fiercebiotech.com/biotech/larimars-friedreichs-ataxia-program-free-last-fda-hold
https://www.globenewswire.com/news-release/2024/05/20/2885137/0/en/Larimar-Therapeutics-Announces-FDA-has-Removed-Partial-Clinical-Hold-for-Nomlabofusp-Program-in-Friedreich-s-Ataxia.html
https://www.globenewswire.com/news-release/2024/05/09/2878601/0/en/Larimar-Therapeutics-Reports-First-Quarter-2024-Operating-and-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/14/2846684/0/en/Larimar-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Operating-and-Financial-Results-and-Provides-Update-on-Nomlabofusp-Development.html
https://www.globenewswire.com//news-release/2024/03/11/2844141/0/en/Larimar-Therapeutics-Announces-the-Dosing-of-the-First-Patient-in-Long-term-Open-Label-Extension-Study-for-Nomlabofusp-in-Patients-with-Friedreich-s-Ataxia.html
https://www.globenewswire.com//news-release/2024/03/06/2841766/0/en/Larimar-Therapeutics-to-Present-at-the-Leerink-Partners-Global-Biopharma-Conference.html
https://www.globenewswire.com//news-release/2024/02/16/2830942/0/en/Larimar-Therapeutics-Announces-Closing-of-Underwritten-Public-Offering-of-Common-Stock-and-Exercise-in-Full-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html
Market Place
Share 
